Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis

Review (35 studies, n=953) noted high response rates (complete remission in 80%; 95% CI 75·5–84·8) after anti-CD19 CAR T-cell therapy can be used to guide the use of therapy in patients with relapsed or refractory acute lymphocytic leukaemia.

The Lancet Haematology